US EditionNovo Nordisk cuts sales forecasts on lower US demand for obesity drug
- On May 1, Novo Nordisk lowered its expectations for revenue and earnings growth in 2025, attributing the revision to weaker-than-anticipated demand for its obesity drug in the U.S. Market.
- The revision followed increased competition from compounded copies of its GLP-1 drugs, made in U.S. Pharmacies despite a recent FDA ban.
- In the first quarter, Novo reported a 19% sales increase to 78 billion kroner, but Wegovy sales declined 13% to 17.36 billion kroner amid market share loss.
- CEO Lars Fruergaard Jorgensen announced a downward revision of the annual forecast, attributing it to slower-than-expected adoption of their branded GLP-1 treatments in the U.S., which has been affected by the swift growth of compounding pharmacies.
- Novo expects growth to recover in the second half of 2025 after compounded copies are removed, but faces ongoing competition from Eli Lilly and market uncertainty.
27 Articles
27 Articles
Why Novo Nordisk Stock Popped After Earnings @themotleyfool #stocks $NVO $HIMS
GLP-1 drugmaker Novo Nordisk's (NYSE: NVO) stock jumped at the open and remains up 3.2% as of 10:20 a.m. ET after the company reported earnings this morning. Novo reported smaller-than-expected Q1 sales and lowered its forecast for the rest of the year. Investors seem more interested in comments about the chances Wegovy sales will improve later this year through the company's partnership with Hims & Hers Health (NYSE: HIMS) as other GLP-1 compou…
Novo Nordisk's Weight Loss Blockbuster Faces Setback From US Compounding Surge, Forecast Trimmed - WW International (NASDAQ:WW), Novo Nordisk (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO) slashed its 2025 sales forecast Wednesday, citing lower-than-expected penetration of its branded GLP-1 weight loss and diabetes treatments in the U.S. market due to competition from compounded versions of the drugs. What Happened: The Danish pharmaceutical giant now expects sales growth of 13-21% at constant exchange rates, down from previous projections. Operating profit growth is now forecast at 16-24%. “We have red…
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
